GLP-1 drugs, initially designed for diabetes management and weight loss, are emerging as a potential treatment for alcoholism and substance use disorders. With over 178,000 alcohol-related deaths annually, their medical intervention could prove crucial. Recent studies show that GLP-1 drugs substantially lower self-reported alcohol intake, binge drinking, and related hospitalizations among individuals with obesity and alcohol use disorder. Specialists from UCLA indicate this is a significant development in addiction treatment, with further studies anticipated to explore these drugs' broader applications in addressing substance use issues.
A study of 153 adults with a body mass index of 30 or higher who were current alcohol drinkers and used a GLP-1 drug found significant reductions in self-reported alcohol intake, binge drinking, and lower scores on alcohol use disorder tests.
A large, 17-year observational study in Sweden indicated that among problem drinkers with both obesity and Type 2 diabetes, GLP-1 drugs substantially decreased the risk for hospitalizations related to alcohol use disorder.
Drs. Bianca Robertson and Jonathan Vargas from UCLA emphasized the potential of GLP-1 and related drugs to treat alcoholism and possibly other substance use disorders.
Alcohol-related diseases kill about 178,000 Americans every year, showing a clear need for more effective medical interventions, as GLP-1 drugs offer a promising solution.
Collection
[
|
...
]